Anti-TNF-α-induced systemic lupus syndrome

Clinical Rheumatology

Volumn 22, Issue 1, 2003, Pages 56-61

  Debandt, M ^a   Vittecoq, O ^b   Descamps, V ^c   Le Loet X ^b   Meyer, O ^c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Anti DNA antibodies; Anti TNF therapies; Antinuclear antibodies; Lupus syndrome; Rheumatoid arthritis

Indexed keywords

ANTINUCLEAR ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PENICILLAMINE; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG TOLERANCE; ERYTHEMA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN DEFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT FAILURE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038460243     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-002-0654-5     Document Type: Article

References (14)

1. Watts RA (2000) Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol 12: 49-52
2. Garrison L, McDonnell N (1999) Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 58 (Suppl 1): 165-169
3. Maini R, St Clair EW, Breedveld F et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939
4. Rutgeerts P, D'Haens G, Targan S et al. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117: 761-769
5. Immunex Corporation, Seattle, WA. Enbrel package insert
6. Centocor Corporation, Malvern, PA. Remicade package insert
7. Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy [letter]. Lancet 359: 579-580
8. Galaria N, Wyerth V, Schumacher R (2000) Leukocytoclastic vasculitis due to etanercept. J Rheumatol 27: 2041-2044
9. Skytta E, Pohjankoski H, Salovainen A (2000) Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 18: 533-534
10. Brion PH, Mittal-Henkle A, Kalunian KC (1999) Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 131: 634
11. Jacob CO, McDevitt HO (1998) Tumor necrosis factor alpha in murine auto-immune lupus nephritis. Nature (Lond) 331: 356-358
12. Gordon C, Ranges GE, Greenspan JS et al. (1989) Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmuneNZB/WF1 mice. J Clin Immunol Immunopathol 52: 421-434
13. Sander O, Rau R (1997) Long term observation of 80 patients treated with TNF-alpha receptor fusion protein (TNF55-IgG1, RO45-2081). Abstract 1157, 61th American College of Rheumatology scientific meeting, Washington, DC, 1997. Arthritis Rheum 40 (Suppl.)
14. Pisetski DS (2000) Tumor necrosis factor alpha blockers and the induction of anti-DNA antibodies. Arthritis Rheum 43: 2381-2382